DK1658056T3 - Tabletter indeholdende 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionsyreethylester eller salte deraf - Google Patents

Tabletter indeholdende 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionsyreethylester eller salte deraf

Info

Publication number
DK1658056T3
DK1658056T3 DK04763952T DK04763952T DK1658056T3 DK 1658056 T3 DK1658056 T3 DK 1658056T3 DK 04763952 T DK04763952 T DK 04763952T DK 04763952 T DK04763952 T DK 04763952T DK 1658056 T3 DK1658056 T3 DK 1658056T3
Authority
DK
Denmark
Prior art keywords
methyl
hexoxyloxycarbonylaminoiminomethyl
ylamino
phenylamino
benzimidazole
Prior art date
Application number
DK04763952T
Other languages
Danish (da)
English (en)
Inventor
Anja Kohlrausch
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK1658056T3 publication Critical patent/DK1658056T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK04763952T 2003-08-16 2004-08-10 Tabletter indeholdende 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionsyreethylester eller salte deraf DK1658056T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10337697A DE10337697A1 (de) 2003-08-16 2003-08-16 Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
PCT/EP2004/008934 WO2005018615A1 (fr) 2003-08-16 2004-08-10 Comprime contenant l'ethylester de l'acide 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionique ou ses sels

Publications (1)

Publication Number Publication Date
DK1658056T3 true DK1658056T3 (da) 2008-09-08

Family

ID=34201585

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04763952T DK1658056T3 (da) 2003-08-16 2004-08-10 Tabletter indeholdende 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionsyreethylester eller salte deraf

Country Status (17)

Country Link
US (1) US20050038077A1 (fr)
EP (1) EP1658056B1 (fr)
JP (1) JP4977462B2 (fr)
AR (1) AR045732A1 (fr)
AT (1) ATE394094T1 (fr)
CA (1) CA2535810C (fr)
CY (1) CY1108218T1 (fr)
DE (2) DE10337697A1 (fr)
DK (1) DK1658056T3 (fr)
ES (1) ES2307041T3 (fr)
PE (1) PE20050342A1 (fr)
PL (1) PL1658056T3 (fr)
PT (1) PT1658056E (fr)
SI (1) SI1658056T1 (fr)
TW (1) TW200509996A (fr)
UY (1) UY28468A1 (fr)
WO (1) WO2005018615A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
DE102005020002A1 (de) * 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
WO2008009638A2 (fr) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh Nouvelles indications portant sur les inhibiteurs directs de la thrombine dans le domaine cardiovasculaire
BRPI0907598A2 (pt) * 2008-03-28 2015-07-21 Boehringer Ingelheim Int Processo para o preparo de formulações de dabigatrana administradas por via oral
US20110123635A1 (en) * 2008-07-14 2011-05-26 Boehringer Ingelheim International Gmbh Method for manufacturing medicinal compounds containing dabigatran
UY32008A (es) 2008-07-28 2010-02-26 Takeda Pharmaceutical Composición farmacéutica
HUP1000069A2 (en) * 2010-02-02 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag New salts for the preparation of pharmaceutical composition
CA2792273A1 (fr) 2010-03-08 2011-09-15 Ratiopharm Gmbh Composition pharmaceutique contenant du dabigatran etexilate
WO2012001156A2 (fr) 2010-07-01 2012-01-05 Krka, Tovarna Zdravil, D.D., Novo Mesto Formes pharmaceutiques posologiques orales comprenant de l'étéxilate de dabigatran et ses sels pharmaceutiquement acceptables
US20140294959A1 (en) 2011-05-20 2014-10-02 Astrazeneca Uk Limited Pharmaceutical Composition of Rosuvastatin Calcium
US20120301541A1 (en) 2011-05-24 2012-11-29 Haronsky Elina Compressed core for pharmaceutical composition
CN102391250B (zh) * 2011-08-29 2013-06-19 石药集团欧意药业有限公司 一种达比加群酯化合物、制备方法及其药物组合物
LT2817000T (lt) 2012-02-21 2021-11-10 Towa Pharmaceutical Europe, S.L. Peroralinės dabigatrano eteksilato farmacinės kompozicijos
US20130345262A1 (en) 2012-06-25 2013-12-26 Boehringer Ingelheim International Gmbh Method for prevention of stroke
AU2013319118B2 (en) * 2012-09-19 2016-03-03 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration with improved elution and/or absorbency
EP2722033A1 (fr) * 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions pharmaceutiques de Dabigatran sous forme de base libre
EP2722034B1 (fr) * 2012-10-19 2020-09-16 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations pharmaceutiques orales comprenant du dabigatran
CN103230378B (zh) * 2013-05-10 2014-12-10 青岛双鲸药业有限公司 一种氯雷他定片的制备方法
EP2853260A1 (fr) * 2013-09-27 2015-04-01 ratiopharm GmbH Préparation pharmaceutique comprenant du dabigatran etexilate bismésylate
CN104784147B (zh) * 2014-01-20 2018-01-23 成都苑东生物制药股份有限公司 一种甲磺酸达比加群酯胶囊药物组合物及其制备方法
IN2014MU01042A (fr) 2014-03-26 2015-10-02 Cadila Healthcare Ltd
WO2016107605A1 (fr) * 2014-12-31 2016-07-07 昆明积大制药股份有限公司 Composition pharmaceutique et procédé de préparation de cette dernière
WO2017103945A1 (fr) * 2015-12-15 2017-06-22 Strides Shasun Limited Compositions pharmaceutiques
WO2017111637A1 (fr) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Composition pharmaceutique comprenant du dabigatran ou un sel pharmaceutiquement acceptable de celui-ci
WO2018104387A1 (fr) 2016-12-07 2018-06-14 Sanovel Ilac Sanayi Ve Ticaret A.S. Compositions de comprimés multicouche de dabigatran
JP2018104425A (ja) * 2016-12-26 2018-07-05 日本ケミファ株式会社 ダビガトランエテキシラートまたはその薬学的に許容される塩を含有する錠剤
JP2018184375A (ja) * 2017-04-27 2018-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ダビガトランエテキシラート又は医薬的に許容されるその塩を含む錠剤及びその製造方法
TR201706848A2 (tr) 2017-05-10 2018-11-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar
WO2019004980A2 (fr) 2017-05-10 2019-01-03 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions pharmaceutiques orales solides d'étéxilate de dabigatran
TR201722323A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari
TR201722186A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin farmasöti̇k kompozi̇syonlari
TR201722630A2 (fr) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
KR880002139B1 (ko) * 1983-04-08 1988-10-17 베링거 인겔하임 리미티드 경구 투여용 정제의 제조방법
CH674148A5 (fr) * 1986-06-24 1990-05-15 Racz Istvan
FR2745500B1 (fr) * 1996-03-04 1998-04-03 Synthelabo Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
DE10133786A1 (de) * 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis
CN100528157C (zh) * 2002-03-07 2009-08-19 贝林格尔英格海姆法玛两合公司 3-[(2-{[4-(己氧羰基氨基-亚氨基-甲基)-苯基氨基]-甲基}-1-甲基-1h-苯并咪唑-5-羰基)-吡啶-2-基-氨基]-丙酸乙酯及其盐的口服施用的投药剂型
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel

Also Published As

Publication number Publication date
PT1658056E (pt) 2008-06-23
JP2007502788A (ja) 2007-02-15
ATE394094T1 (de) 2008-05-15
WO2005018615A1 (fr) 2005-03-03
DE502004007069D1 (en) 2008-06-19
US20050038077A1 (en) 2005-02-17
JP4977462B2 (ja) 2012-07-18
AR045732A1 (es) 2005-11-09
CA2535810A1 (fr) 2005-03-03
CY1108218T1 (el) 2014-02-12
PE20050342A1 (es) 2005-06-17
UY28468A1 (es) 2005-03-31
EP1658056A1 (fr) 2006-05-24
ES2307041T3 (es) 2008-11-16
PL1658056T3 (pl) 2008-10-31
CA2535810C (fr) 2013-06-25
TW200509996A (en) 2005-03-16
SI1658056T1 (sl) 2008-08-31
EP1658056B1 (fr) 2008-05-07
DE10337697A1 (de) 2005-03-24

Similar Documents

Publication Publication Date Title
DK1658056T3 (da) Tabletter indeholdende 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionsyreethylester eller salte deraf
DK1660482T3 (da) 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-mehtyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsyre-ethylester-methansulfonat og dennes anvendelse som lægemiddel
EA200702541A1 (ru) Полиморфы этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты
CY2012031I2 (el) Χορηγουμενη απο του στοματος φαρμακοτεχνικη μορφη για τον 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλ}-1-μεθυλ-1η-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλ-αμινο]-προπιονικο αιθυλεστερα ή τα αλατα αυτου
WO2006114415A3 (fr) Sels de l'ethylester d'acide 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionique physiologiquement compatibles
NO20043793L (no) Nikotinamidderivater anvendelige som PDE4 inhibitorer
DK2316430T3 (da) Farmaceutiske sammensætninger med kontrolleret frigivelse omfattende en fumarsyreester
CY2013015I1 (el) Πολυμορφο του 4-[2-[4-[1-(2-αιθοξυαιθυλ)-1η-βενζιμιδαζολ-2-υλ]-1-πιπepιδινυλ]αιθυλ]αιθυλ-αλφα, αλφα-διμεθυλ-βενζενοξικου οξεος
IS7808A (is) Aðferð til nýmyndunar í iðnaði á metýldíester 5-amínó-3-karboxýmetýl-4-sýanó-2-þíófenkarboxýlsýru
EE200200284A (et) (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhappe peenestatud vorm
EE200200278A (et) (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhappe kristalne vorm
DE602004011548D1 (de) 4-aminochinolin-3-carbonsäureamid-derivate als pde4-hemmer
TWI347947B (en) Process for preparing [4-(1,3,4-oxadiazol-2-yl)phenyl] boronic acid and use thereof
DK1599455T3 (da) 4-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og aterosclerose
IS7489A (is) (2-((2-alkoxý)-fenýl)-hringpent-1-enýl) arómatískkarbó- og heteróhringtengd sýra og afleiður
IL199389A (en) 2-Oxide salt ((4 - (1-methyl-4-pyridine-4-yl) -h1-pyrrolysis-3-yl) phenoxy) quinoline
NO20054141D0 (no) Substituerte 2-(diaza-bicykloalkyl)pyrimidonderivater
NO20043400L (no) Fremgangsmater for nukleinsyreamplifisering
DK2010538T3 (da) Fremgangsmåde til fremstilling af [(1R), 2S]-2-aminopropionsyre 2-[4-(4-fluor-2-methyl-1H-indol-5-yloxy)-5-methylpyrrol]2,1-f-[1,2,4-triazin-6-yloxy]-1-methylethylester
DK1497290T3 (da) Fremgangsmåde til fremstilling af syresalte af gemifloxacin
IS7056A (is) Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3 [4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxý própansýru og insúlín
AU2003237394A1 (en) Crystalline (2-(4-((4-chlorophenyl)-phenyl methyl)-1-piperazinyl) ethoxy) acetic acid dihydrochloride
GB0227205D0 (en) Heat sensitive composition comprising benzoic acid derivatives
FR2858530B1 (fr) Support informatique universel
ITMI20042092A1 (it) Metodo per l'allestimento di pareti di ambienti e ambienti cosi' ottenuti